ArticleThe World Allergy Organization journal2025
Clinical profile, prevalence, and burden of chronic spontaneous urticaria in the United States.
Article in The World Allergy Organization journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Corticosteroid-Associated Adverse Events in Chronic Spontaneous Urticaria: A US Claims Data Study.Dermatology and therapy · 2026Article
- Efficacy of Remibrutinib versus Dupilumab at Early Timepoints in Chronic Spontaneous Urticaria: US Phase 3b Study Design (RECLAIM).Dermatology and therapy · 2026Article
- Basophil FCER1A and PTAFR Gene Expression Profiles Correlate With Disease Severity in Chronic Spontaneous Urticaria.Clinical and translational allergy · 2026Article
- Disease Control, Activity and Quality of Life in Chronic Spontaneous Urticaria: A Cross-Sectional Study from Kazakhstan.Diagnostics (Basel, Switzerland) · 2026Article
- Psychological Wellbeing of Patients with Chronic Spontaneous Urticaria and Its Relation to Their Overall Health-Related Quality of Life.Clinical, cosmetic and investigational dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Data on the prevalence and burden of chronic spontaneous urticaria (CSU) are limited in the United States (US). Objective: To estimate the burden, clinical profile, and prevalence of diagnosed CSU in the United States. Methods: Data from respondents with physician-diagnosed CSU were collected from the 2019 National Health and Wellness Survey (NHWS). Outcomes assessed included diagnosed CSU prevalence, demographics, clinical profile, and burden using the 36-item Short Form Survey version 2 (SF-36v2; physical and mental component summary [PCS and MCS] scores), Short-Form 6 Dimension (SF-6D) and EuroQol-5 Dimension (EQ-5D) utility scores, Dermatology Life Quality Index (DLQI), Patient Health Questionnaire-9 (PHQ-9), General Anxiety Disorder-7 (GAD-7), Work Productivity and Activity Impairment (WPAI) questionnaire, and healthcare resource utilization over the past 6 months. Results: Among 74,994 respondents, 815 reported physician-diagnosed chronic urticaria, with 635 (77.9%) having CSU. The weighted prevalence (95% confidence interval) of diagnosed CSU was 0.78% (0.78%-0.78%). The mean (standard deviation [SD]) age at diagnosis was 37.0 (17.1) years, and 51.7% of respondents were female. Lower (worse) MCS and PCS scores were observed than in the overall NHWS population. The mean (SD) SF-6D and EQ-5D health utility scores were 0.54 (0.14) and 0.62 (0.34), respectively. The mean (SD) DLQI score was 13.8 (11.2), with more than 74.0% of respondents reporting anxiety (GAD-7 ≥5) and depression (PHQ-9 ≥5). Mean percent (SD) scores for absenteeism, presenteeism, overall work impairment, and activity impairment were 36.5% (26.1), 67.2% (34.9), 73.1% (34.2), and 62.6% (34.1), respectively. The percentage of patients visiting any healthcare provider, an emergency department, or requiring hospitalization was 96.5%, 60.2%, and 55.9%, respectively. Conclusion: This real-world study reveals a higher prevalence of diagnosed CSU in the United States than previously reported, along with significant humanistic and economic burdens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.